Cyclin-dependent kinase 4 (CDK4)

Overview

Cyclin-dependent kinase 4 (CDK4) is a serine/threonine protein kinase that plays a central role in regulating cell cycle progression, specifically the transition from the G1 phase to the S phase. CDK4 exerts its activity by forming heterodimeric complexes with its regulatory partners, the D-type cyclins (cyclin D1, D2, and D3), which are required for kinase activation. Upon complex formation, CDK4 phosphorylates the retinoblastoma protein (Rb), releasing the transcription factor E2F and enabling transcription of genes necessary for S-phase entry and DNA replication. This mechanism positions CDK4 as a critical gatekeeper of proliferative signaling in normal development and a frequent target of dysregulation in human malignancies. CDK4 is closely related to and functionally redundant with cyclin-dependent kinase 6 (CDK6) in many cellular contexts, and the two are commonly referred to jointly as CDK4/6.

Given its pivotal role in driving cell division, CDK4 has emerged as a major therapeutic target in oncology. Aberrant CDK4 activity — through gene amplification, cyclin D overexpression, or loss of endogenous inhibitors such as p16/CDKN2A — is implicated in a broad range of Cancers. Small-molecule inhibitors selectively targeting CDK4/6 have been developed and approved clinically, most prominently for hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer, where these agents have transformed the treatment landscape in combination with endocrine therapy.

Recent Publications Summary

Recent studies have continued to evaluate Cyclin-dependent kinase 4 (CDK4) as both a diagnostic marker and a therapeutic target. In jaw osteosarcoma, immunohistochemical assessment showed significantly higher CDK4 expression in low-grade osteosarcoma than in juvenile trabecular ossifying fibroma, which was negative for CDK4 in all cases; osteoblastoma showed only inconsistent, focal positivity, whereas osteosarcoma showed strong, diffuse expression 42467383Jul. These findings support the use of CDK4, together with MDM2, in distinguishing malignant from benign osseous lesions of the jaw 42467383Jul.

Several publications focused on CDK4/6 inhibition in breast cancer and related tumor models. A new series of triazolopyrimidine derivatives was synthesized as selective CDK4 inhibitors, and molecular docking indicated strong binding to the CDK4 active site; the lead compound showed antiproliferative activity against MCF-7 and MDA-MB-231 cells with limited toxicity to normal fibroblasts 42187623May. In another study, a near-infrared-II fluorescent probe built from palbociclib or ribociclib conjugated to indocyanine green enabled real-time visualization of CDK4/6 inhibitor activity in hormone receptor-positive, HER2-negative breast cancer models, with early decreases in tumor fluorescence preceding changes in tumor size and correlating with reduced pRB and MKI67 expression 41825845Mar. A separate report described a circular-by-design polymer delivery platform that loaded palbociclib at high capacity and improved selective delivery to cancer cells 42095698May.

Mechanistic and combination-therapy studies further linked CDK4/6 targeting to immune modulation and resistance. CDK4/6 inhibitors were reported to shift tumor-associated macrophages from an M2-like to an M1-like phenotype, enhance macrophage phagocytosis, and activate effector T cell responses; in preclinical breast cancer models, combining CDK4/6 inhibition with CD47 blockade suppressed tumor growth 42307815Jun. In dedifferentiated liposarcoma, palbociclib was described as delaying disease progression, and a phase 2 study evaluated palbociclib plus retifanlimab based on the rationale that CDK4/6 inhibition may increase intratumoral inflammation and synergize with immune checkpoint inhibition 42082272May. Resistance-related work in breast cancer identified PCK1 as a contributor to CDK4/6 inhibitor resistance through interaction with Cyclin D3, and showed that everolimus and auranofin could synergize with CDK4/6 inhibitors to suppress tumor growth 41748011Feb. Additional clinical reports noted variable ribociclib exposure in the setting of renal impairment and raised concern for atrial arrhythmias with CDK4/6 inhibitors in HR+/HER2-negative breast cancer 42159622May41903892Mar.

What Changes, What Holds

1. CDK4 can help distinguish malignant jaw osteosarcoma from benign osseous lesions
REINFORCES Immunohistochemistry here extends CDK4’s established value as a marker of proliferative malignancy rather than changing its biological role. The new work suggests practical diagnostic utility in jaw bone tumors, especially alongside MDM2, but it does not alter the baseline account of CDK4 as a cell-cycle kinase or therapeutic target. The main implication is narrower and clinical: CDK4 expression may support separation of low-grade osteosarcoma from benign mimics 42467383Jul.

2. New CDK4 inhibitors and delivery/monitoring tools sharpen, but do not replace, the therapeutic model
REINFORCES These studies strengthen the existing oncology use case by adding more selective inhibitors, better delivery, and a way to visualize target engagement in real time. They do not challenge the established view that CDK4/6 blockade is therapeutically useful in HR+/HER2-negative breast cancer; instead, they suggest the field is moving toward improved precision, monitoring, and formulation. The imaging probe is especially useful as a pharmacodynamic tool, not a new biological role 42187623May41825845Mar.

3. CDK4/6 inhibition is expanding into immune and resistance biology, with safety questions emerging
NEW DIRECTION Work on macrophage polarization, CD47 blockade, and checkpoint combinations adds a role for CDK4/6 targeting in immune modulation that the Overview does not cover, so this is an added mechanism rather than a contradiction. Resistance-linked findings and combination strategies also suggest that CDK4/6 inhibition may need to be paired with other agents to remain effective. Reports of variable exposure in renal impairment and possible atrial arrhythmias raise tolerability concerns that warrant clinical confirmation 42307815Jun42082272May.

Overview update candidates: CDK4 as a diagnostic adjunct in jaw osteosarcoma; immune-modulatory and combination-therapy roles for CDK4/6 inhibition; emerging safety and pharmacokinetic concerns with CDK4/6 inhibitors.